Ting Henry H, Yang Eric H, Rihal Charanjit S
Cardiac Catheterization Laboratory, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Ann Intern Med. 2006 Oct 17;145(8):610-7. doi: 10.7326/0003-4819-145-8-200610170-00010.
Optimal treatment for ST-segment elevation myocardial infarction depends on early diagnosis and rapid selection of the appropriate reperfusion strategy. Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy at PCI-capable hospitals. For hospitals without PCI capability, there are 2 reperfusion strategies, primary PCI and thrombolytic therapy, which are both supported by clinical evidence and national guidelines. Transferring patients for primary PCI may cause delays and requires established, proven protocols, systems, and networks to achieve minimal door-to-balloon times. The authors review the available data and present a systematic, evidence-based approach in a simple framework to enable noncardiovascular and cardiovascular physicians to select the optimal reperfusion strategy. The framework is based on available data from clinical trials and local circumstances from clinical practice by incorporating duration of symptoms (fixed ischemia time) and anticipated transport delays to a PCI-capable facility (incurred ischemia time).
ST 段抬高型心肌梗死的最佳治疗取决于早期诊断和迅速选择合适的再灌注策略。在有能力进行经皮冠状动脉介入治疗(PCI)的医院,直接经皮冠状动脉介入治疗是首选的再灌注策略。对于没有 PCI 能力的医院,有两种再灌注策略,即直接 PCI 和溶栓治疗,这两种策略均有临床证据和国家指南支持。将患者转运至进行直接 PCI 治疗可能会导致延误,这需要既定的、经过验证的方案、系统和网络,以实现最短的门球时间。作者回顾了现有数据,并在一个简单的框架内提出了一种系统的、基于证据的方法,以使非心血管科和心血管科医生能够选择最佳的再灌注策略。该框架基于临床试验的现有数据以及临床实践中的当地情况,纳入了症状持续时间(固定缺血时间)和预计转运至有 PCI 能力的机构的延误时间(额外缺血时间)。